Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
U.S. Patient Utilization Grew 33%, Year Over Year
DANVERS, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today reported third quarter fiscal 2018 revenue of $154.0 million, an increase of 34% compared to revenue of $114.7 million for the same period of fiscal 2017.
Financial and operating highlights during the third quarter of fiscal 2018 include:
- Worldwide revenue from Impella heart pumps totaled $148.0 million, an increase of 36% compared to revenue of $109.2 million during the same period in the prior year. U.S. revenue from Impella pumps grew 30% to $130.7 million and U.S. patient usage grew 33%.
- Outside the U.S., revenue from Impella heart pumps totaled $17.3 million and was up 94% year over year, predominantly from Germany, which recorded $11.4 million, up 71%. Additionally, the Company recorded $1.1 million in revenue from Japan.
- The installed base for Impella 2.5® heart pumps in the U.S. grew by an additional 10 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,181 sites. The installed customer base for Impella CP® heart pumps grew by 41 new U.S. hospitals, bringing the total number of Impella CP sites to 1,134. The installed customer base for Impella 5.0® heart pumps grew by 14 new U.S. hospitals, bringing the total number of Impella 5.0 sites to 498.
- An additional 36 sites made initial purchases of Impella RP® heart pumps during the quarter, bringing the total number of sites to 222.
- Third quarter fiscal 2018 GAAP net income was $13.4 million, or $0.29 per diluted share. Third quarter fiscal 2018 adjusted* net income before the recently enacted Tax Reform Act was $32.2 million, or $0.70 per diluted share, compared to $15.4 million or $0.34 per diluted share for the prior year period. Third quarter fiscal 2018 adjusted* net income included income tax expense adjustments of approximately $18.8 million, or $0.41 per diluted share due primarily to the recently enacted Tax Reform Act and excess tax benefits on employee share-based compensation awards, which were not applicable in the prior year period.
- Gross margin was 83.8% compared to 83.4% in the prior year.
- Operating income was $44.8 million, or 29.1% operating margin, compared to $25.4 million, or 22.2% operating margin in the prior year.
- The Company generated $56.7 million in cash from operating activities during the third quarter. Cash, cash equivalents and marketable securities totaled $350.7 million as of December 31, 2017, compared to $319.2 million at September 30, 2017. The Company currently has no debt.
- In October 2017, the Company officially closed on the purchase of its Danvers, Massachusetts global headquarters for $16.5 million.
"It is an exciting time for the company as we collaborate with our customers to improve patient outcomes and the standard of care for circulatory support," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "The Field of Heart Recovery is growing and Abiomed is well positioned to capture the $5 billion U.S. market opportunity, while planting the seeds for future growth in global markets."
FISCAL YEAR 2018 OUTLOOK
The Company is increasing its fiscal year 2018 revenue guidance again to approximately $583 million, an increase of approximately 31% from the prior year. This compares to the Company's prior fiscal 2018 guidance of $565 million to $575 million and a 27% to 29% increase from the prior year. This guidance projects revenue to be approximately $164 million for the fourth quarter of fiscal 2018. The Company is increasing its fiscal year guidance for GAAP operating margin to approximately 26%. This compares to the Company's prior fiscal 2018 guidance of 23% to 25%.
The Company will host a conference call to discuss the results on Thursday, February 1, 2018, at 8:00 a.m. EST. Michael R. Minogue, Chairman, President and Chief Executive Officer and Robert L. Bowen, former Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EST February 1, 2018 through 11:00 a.m. EST on February 8, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 2967997.
The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S. and in certain foreign countries. Impella 2.5, Impella 5.0, and Recovering hearts. Saving lives. are trademarks of Abiomed, Inc.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, future opportunities, expected regulatory approvals and fiscal year 2018 revenue and operating margin expectations. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
* USE OF NON-GAAP MEASURES
To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP financial measures: adjusted net income and adjusted net income per diluted share. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding the provisional income tax expense related to the Tax Reform Act; and the excess tax benefits associated with share-based compensation arrangements. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to its historical performance and liquidity. The Company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company's business.
Adjusted net income and adjusted net income per diluted share. The Company defines adjusted net income as net income, net of the provisional income tax expense related to the Tax Reform Act and the excess tax benefits associated with share-based compensation arrangements. The Company defines adjusted net income per diluted share as adjusted net income divided by diluted shares used for GAAP purposes which are calculated as the weighted average outstanding shares plus dilutive potential shares outstanding during the period. See below for a reconciliation of adjusted net income and adjusted net income per diluted share to net income and net income per diluted share.
For further information please contact:
Director, Investor Relations
|Abiomed, Inc. and Subsidiaries|
|Consolidated Balance Sheets|
|(in thousands, except share data)|
|December 31, 2017||March 31, 2017|
|Cash and cash equivalents||$||50,502||$||39,040|
|Short-term marketable securities||250,751||190,908|
|Accounts receivable, net||64,862||54,055|
|Prepaid expenses and other current assets||9,192||8,024|
|Total current assets||422,198||326,958|
|Long-term marketable securities||49,485||47,143|
|Property and equipment, net||107,977||87,777|
|In-process research and development||16,241||14,482|
|Long-term deferred tax assets, net||75,201||34,723|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Current portion of capital lease obligation||-||799|
|Total current liabilities||75,353||69,617|
|Other long-term liabilities||466||3,251|
|Long-term deferred tax liabilities||878||783|
|Capital lease obligation, net of current portion||-||15,539|
|Commitments and contingencies|
|Class B Preferred Stock, $.01 par value||-||-|
|Authorized - 1,000,000 shares; Issued and outstanding - none|
|Common stock, $.01 par value||443||437|
|Authorized - 100,000,000 shares; Issued - 45,995,445 shares at December 31, 2017 and 45,249,281 shares at March 31, 2017|
|Outstanding - 44,271,905 shares at December 31, 2017 and 43,673,286 shares
at March 31, 2017
|Additional paid in capital||605,697||565,962|
|Retained earnings (accumulated deficit)||103,610||(46,959||)|
|Treasury stock at cost - 1,723,540 shares at December 31, 2017 and 1,575,995 shares at March 31, 2017||(66,622||)||(46,763||)|
|Accumulated other comprehensive loss||(10,646||)||(20,606||)|
|Total stockholders' equity||632,482||452,071|
|Total liabilities and stockholders' equity||$||719,602||$||550,414|
|Abiomed, Inc. and Subsidiaries|
|Consolidated Statements of Operations|
|(in thousands, except per share data)|
Three Months Ended
Nine Months Ended
|Funded research and development||33||50||111||83|
|Costs and expenses:|
|Cost of product revenue||24,994||18,987||68,483||51,366|
|Research and development||17,706||16,349||54,027||50,061|
|Selling, general and administrative||66,556||53,935||187,233||158,053|
|Income from operations||44,766||25,403||109,570||61,144|
|Investment income, net||969||457||2,385||1,068|
|Other expense, net||(81||)||(34||)||(25||)||(225||)|
|Income before income taxes||45,654||25,826||111,930||61,987|
|Income tax provision||32,208||10,394||36,607||24,770|
|Basic net income per share||$||0.30||$||0.36||$||1.71||$||0.86|
|Basic weighted average shares outstanding||44,247||43,431||44,095||43,125|
|Diluted net income per share||$||0.29||$||0.34||$||1.65||$||0.83|
|Diluted weighted average shares outstanding||45,869||44,770||45,731||44,597|
|Abiomed, Inc. and Subsidiaries|
|Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures|
|(in thousands, except per share data)|
Three Months Ended
Nine Months Ended
|GAAP net income||$||13,446||$||15,432||$||75,323||$||37,217|
|GAAP net income includes the effect of the following items:|
|Effect of the Tax Reform Act on net deferred tax assets *||21,957||-||21,957||-|
|Excess tax benefits related to stock-based compensation awards **||(3,214||)||-||(24,490||)||-|
|Adjusted net income||$||32,189||$||15,432||$||72,790||$||37,217|
|GAAP net income per share - diluted||$||0.29||$||0.34||$||1.65||$||0.83|
|GAAP diluted net income per share includes the effect of the following items:|
|Effect of the Tax Reform Act on net deferred tax assets *||0.48||-||0.48||-|
|Excess tax benefits related to stock-based compensation awards **||(0.07||)||-||(0.54||)||-|
|Adjusted net income per share - diluted||$||0.70||$||0.34||$||1.59||$||0.83|
|Shares used in calculation of adjusted net income per diluted share||45,869||44,770||45,731||44,597|
|* On December 22, 2017, the Tax Cut and Jobs Act ("the Tax Reform Act") was enacted into law. This new tax law, among other items, reduces the U.S. federal statutory corporate income tax rate from 35% to 21% effective January 1, 2018. During the three and nine months ended December 31, 2017, the Company recorded a one-time income tax expense adjustment related to the revaluation of its deferred taxes due to a reduction of the U.S. federal statutory corporate income tax rate.|
|** In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required.|
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Bermuda Principles event merges science and business20.2.2018 16:36 | Pressemelding
HAMILTON, Bermuda, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Scientists and researchers from around the world are gathering in Bermuda this week for the second edition of a conference exploring the field of genetic research. Premier the Hon David Burt will officially open "Bermuda Principles: Impact on Splicing" Wednesday evening at the Fairmont Southampton. The conference, which runs through Saturday, has registered 50 delegates, along with an impressive roster of 36 speakers and panellists from 11 countries, including Australia, Denmark, Switzerland and South Africa. Among the attendees are prominent geneticists, scientists, professors, researchers, PhD students working in international labs, biotech representatives and investors. "I am elated to see the growth of the conference since last year's event," said Bermudian Dr. Carika Weldon, a biomedical researcher with her own lab at De Montfort University, UK, who conceived of the event and launched it last February. "My main aim has been to p
Globecomm Joins Amazon Web Services Partner Network20.2.2018 16:00 | Pressemelding
Highlights Globecomm establishes direct access to Amazon Web Services (AWS) Direct Connect at key datacenter locations. Customers in U.S. Government, media and entertainment, enterprise video and the Internet of Things (IoT) can interoperate cloud-based services with Globecomm's global satellite and fiber network to reduce capital expenditure and ramp up networks and services faster. Globecomm's suite of Software-as-a-Service (SaaS) applications run on AWS, accessible across both AWS and Globecomm's global network. Globecomm's team in place to design, develop and deliver cloud-centric as well as hybrid architectures for end-to-end services and customer solutions. HAUPPAUGE, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Globecomm announced today that it has joined the Amazon Web Services (AWS) Partner Network (APN) as a Standard Technology Partner. This agreement will enable Globecomm to seamlessly interoperate its global satellite and fiber network with AWS's storage, compute and cloud conte
Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy20.2.2018 15:41 | Pressemelding
LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Information Department at Elite Capital & Co. Limited (ECC), announced today that the company features in the specialized and prestigious New European Economy Magazine in its January 2018 issue in Britain and the European Union countries as the "Infrastructure Project Finance Provider 2018". The award is the result of focused efforts and synergy between the ECC Board of Directors and our employees and strategic partners all over the world over the past years. It also reflects the ability of the Company's strategy to adapt to the prevailing global economic circumstances and testifies to the viability of the planning process adopted by the Board of Directors. Dr. Faisal Khazaal, Chairman of Elite Capital & Co. commented on the occasion, "I should thank Mr. George Matharu, President of ECC and his Board Members who make ceaseless efforts towards ensuring that ECC continues to occupy a prestigious position in the field of finance and economy in
New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success20.2.2018 15:26 | Pressemelding
Powerful mind mapping and information visualization software introduces its most robust Mac version yet; complete with new diagram types, an expanded template library, advanced mapping capabilities, and improved sharing options OTTAWA, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Introduced today, MindManager® 11 for Mac brings new elegance and efficiency to the way individuals and teams organize ideas, tackle tasks, and achieve their goals. Already a leader in mind mapping and information visualization on the Mac, MindManager's new release offers advanced mapping capabilities, new diagram types and templates, and easy ways to share and publish your work - all delivered within a redesigned interface optimized to enhance productivity. Individuals, small businesses, and global organizations rely upon MindManager to efficiently brainstorm and organize ideas, communicate knowledge effectively, and execute project success. MindManager enables users to turn unstructured ideas and information into dynam
Inspiration to Seek Shareholder Approval for Forward Split of its Common Shares20.2.2018 15:00 | Pressemelding
TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) would like to announce that, further to its press release dated January 18, 2018, it will be seeking shareholder approval for a special resolution authorizing the directors to effect a forward split of the Corporation's common shares on a one (1) for two (2) basis. As stated in the Corporation's press release of January 18, 2018, Inspiration has scheduled its annual and special meeting of shareholders for May 3, 2018. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements based on assumptions, uncertainties and management's best estimates of future events. Actual results may differ materially from those currently antici
Ovum Survey Finds NetSfere Among The Top 3 Most Widely Deployed Secure Enterprise Messaging Services20.2.2018 15:00 | Pressemelding
NetSfere is the third most used enterprise platform, clearly outpacing legacy enterprise communication vendors CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- A report by Ovum, a market-leading research and consulting firm, commissioned by Infinite Convergence Solutions, a global leader in messaging and mobility solutions, finds that within just a few short years of launching, NetSfere is ranked as the third most used enterprise messaging service behind Skype Business and Cisco's Spark. In addition to the need for a secure messaging service, the report shows enterprise demand for communication services that enable collaboration beyond messaging. NetSfere's combined HD voice, video and text capabilities - all preferred means of communication in one encrypted platform - validates its ranking among the top services for enterprises. "With messaging services advancing into all-in-one communications platforms, there's a greater propensity for widespread business use - but also major security risk
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom